The bipartisan-backed bill requires drug makers to report production interruptions and discontinuations to the FDA in advance. The new law also gives the FDA authority to speed approval of applications for drugs in short supply and lifts certain caps on narcotic ingredients to ensure sufficient supply for pain management, anesthesia and other uses.
Additionally, the legislation creates a user fee program for generic drugs, intended to jumpstart FDA approval of generics. It also allows hospitals within health systems to share repackaged drugs when they are in short supply.
More Articles Related to the FDA:
FDA Issues Class 1 Recall for Maquet Anesthesia System
FDA’s Unique Device Identification Rule Represents Progress, but Quicker Changes Needed
FDA Proposes Identification System for Medical Devices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
